Sponsors
Blog
Where our team of editors discuss what they think about the current NGP US Issues.
Editor NGP Europe
Tough competition
The battle between generics and branded products has been going on for a long time: the claims and counter claims over Aspirin, for example, have been in process since the early 20th century.06 Aug 2009
White Papers
Focus Area: Drug Discovery
Transformers
Pfizer is undergoing a transformation. Since the failure of its promising pill Torcetrapib, all of Pfizer’s operating divisions have been closely examined to decide how they can help the company address the challenges ahead.
Expanding into biotherapeutics
Biotherapeutics, believes Dr. Tim Riley, Vice President and Managing Director of the Pharmaceutical Business Operations at Waters Corporation, is rapidly growing. NGP asked him how Water’s mass spectrometry systems help to characterise these therapeutics in order to control their quality and efficacy.
Behavioural pharmacology
MPI Research’s Dr. David Gauvin discusses predictive methodologies to identify and characterise potential abuse liability issues.
Lentiviral vectors: from research to gene therapy
Boro Dropulic, Founder and CEO of Lentigen Corporation, about highly efficient and stable gene delivery offered by Lentiviral vectors.
Automated blood sampling
NGP asked DiLab’s Per Dannhusen what to bear in mind when switching to automated blood sampling.
Source: www.ngpharma.eu.com© 2010 GDS Publishing Ltd. All rights reserved.